Protein crystal growth in a microgravity environment by Bugg, Charles E.
N89 - 2 0 2  9 2  
PROTEIN CRYSTAL GROWTH IN A MICROGRAVITY ENVIRONMENT 
Nasa Contract Number: NAS8-36611 
Principal Investigator: Charles E. Bugg 
Co-Investigators: See attached list 
Note: This report is based primarily on the contents of two recent publications 
describing the background and results of the space shuttle experiments: 
1. 
2. 
I. 
Charles E. Bugg 
“The Future of Protein Crystal Growth“, Journal of Crystal Growth 76 (1986) 
535-544. 
Lawrence J. DeLucas, F. L. Suddath, Robert Snyder, Robert Naumann, M. 
Beth Broom, Marc Pusey, Vaughn Yost, Blair Herren, Daniel Carter, Bill 
Nelson, Edward J. Meehan, A. McPherson and C. E. Bugg 
“Preliminary Investigations of Protein Crystal Growth Using the Space 
Shuttle”, Journal of Crystal Growth 76 (1986) 681-693. 
Introduction 
Crystallography is a powerful method for determining the three-dimensional 
structures of complicated biological molecules. Crystallographic studies of proteins 
and nucleic acids have played key roles in establishing the structural foundations of 
molecular biology and biochemistry, and for revealing structure/function 
relationships tha t  are of major importance in  understanding how other 
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macromolecules operate in biological systems. More recently, crystallographic 
studies of biological macromolecules have become of considerable interest to the 
pharmaceutical, biotechnology and chemical industries, as promising tools in 
protein engineering, drug design, and other applications to biological systems. 
The elaborate information that can be learned from the three-dimensional 
structure of a protein is useful in a variety of ways. From the basic biological view- 
point, this information underlies our current understanding of the mechanisms by 
which enzymes, receptors, hormones, etc. function in biological systems. Within the 
pharmaceutical industry, protein structure information can be helpful in the 
development of novel drugs. Since many pharmaceutical agents exercise their 
activity by interacting with proteins, knowledge of the three-dimensional structure 
of a target protein can be used to design compounds that selectively bind to protein 
sites and thereby inhibit the activities of the protein (1-5). Several major 
pharmaceutical companies have now established protein crystallography groups to 
pursue this approach of rational drug design. 
Another highly promising application of protein crystallography is in protein 
engineering (6-15). Readily available techniques of molecular biology permit 
investigators to specifically alter protein molecules by site-directed mutagenesis. In 
general, the most promising approaches to protein engineering depend upon detailed 
structural information about the proteins of interest. Although the techniques that 
are involved in protein engineering are under intense development a t  this stage, it is 
generally accepted that these methods will prove to be of tremendous practical value 
for the design of modified enzymes, and for the development of proteins that have 
carefully engineered physical and biological properties. There is likely to be a 
continued expansion of interest in applications of site-directed mutagenesis, and 
several protein crystallography groups in academic institutions and in  
biotechnology-oriented companies are expanding their programs in order to exploit 
the potential of this technology. 
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An additional use of protein crystallography is in the design of synthetic 
vaccines (16- 19). Several recent studies have indicated that effective vaccines might 
be made from synthetic peptides that are representative of protein segments found 
on the surfaces of target proteins. Protein crystallography provides one of the most 
effective techniques for locating those peptides. 
Because of the widespread fundamental and practical importance of knowing 
the structures of biological materials, the overall interest in protein crystallography 
has increased greatly during the past few years. At the present time, protein 
crystallography really has no substitute: It is the only general technique available 
for elucidating the precise atomic arrangements within complicated biological 
molecules. Other techniques, such as two-dimensional NMR spectroscopy, are likely 
to become more and more useful during the next few years, but it is unlikely that any 
of these techniques will be competitive with X-ray crystallography in the near future 
for routinely determining three-dimensional structures of large proteins and other 
complicated biological macromolecules. Unfortunately, protein crystallography has 
the unique requirement that relatively large, high-quality single crystals must be 
obtained before a structural study can be pursued. Therefore, protein crystal growth 
has become a topic of considerable importance. 
Unfortunately, all of the major steps that are involved in determining a protein 
structure by crystallographic techniques are subject to a number of experimental 
dificulties. Most of the proteins that have been studied during the past three 
decades required many years of intense effort before the complete three-dimensional 
structure was known. Consequently, until recently, there was limited interest in 
using protein crystallography as a general tool in biological research, and protein 
crystallography programs were limited to a few laboratories, primarily in academic 
institutions. 
Several recent advances i n  the technologies required for protein 
crystallographic studies have made i t  much easier to determine the crystal structure 
of a protein or other macromolecule: 
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(1) Recombinant DNA techniques have made it possible to obtain proteins that 
would have been impossible to isolate in sufficient quantities for X-ray diffraction 
studies several years ago (6-13). 
(2) Synchrotron radiation sources, which provide X-ray beams with intensities that 
are several orders of magnitude greater than those available from laboratory 
sources, permit data sets to be collected rapidly, and from relatively few crystals (22- 
27). Synchrotrons also offer the capability of selecting specific wavelengths, and this 
capability might eventually prove to be of value in eliminating the need for heavy- 
atom derivatives in some specific cases (26). 
(3) Electronic area detector systems have been developed, and are now available 
commercially from several different vendors. These two-dimensional detector 
systems permit data to be measured much faster than was possible with the single- 
counter detector systems that have been widely used in the past (28,29). 
(4) Recent applications of anomalous dispersion measurements have permitted 
protein structures to be determined without the addition of heavy-atom derivatives 
(30-32). Intense efforts are in progress in a number of laboratories to develop direct 
methods for determining protein phases, which are analogous to the powerful 
statistical techniques that have essentially eliminated the need for heavy-atoms in 
"small molecule" crystallography (33-39). 
(5) Computer graphics methods have revolutionized techniques that are used to 
construct protein models from electron density maps (40, 41). Computer graphics 
techniques have also made it possible to understand and to interpret structures with 
ease (41, 42), and the widespread use of computer graphics in the pharmaceutical, 
chemical and biotechnology industries has served to further stimulate interest in 
applications of protein crystallography. 
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(6) A variety of approaches and software systems have been developed for refining 
protein structures, once an initial model is constructed from the electron density 
maps (43-46). Refinements are now being pursued routinely to high resolutions, and 
the increasing availability of super computers will make refinements of large 
proteins relatively routine (47). 
It is noteworthy that the major advances in protein crystallography involve 
those experimental steps that are of importance after suitable crystals have been 
obtained. For the most part, the general procedures that are used for growing 
protein crystals have not changed appreciably during the past few years. Most 
protein crystals are still grown by brute-force, trial-and-error methods, which 
require investigations of large numbers of experimental conditions in hopes of 
finding the combination that produces usable crystals. However, once good crystals 
of a particular protein have been obtained, the crystallography often moves along at 
a rapid rate. 
2. Current problems in protein crystal growth 
Nearly any protein crystallographer would immediately point to protein 
crystal growth as being the major bottleneck in the further widespread development 
in this field. Despite intensive efforts, a number of interesting proteins have never 
been crystallized. Many proteins and other biological macromolecules may yield 
small micro-crystals readily, but i t  can then take several years of tedious trial-and- 
error experimentation before these micro-crystrals can be induced to grow large 
enough for a complete structural analysis. Even when large crystals are obtained, 
the crystals of essentially all biological macromolecules diffract very poorly, due to 
various types of internal disorder within these crystals. 
Most protein crystallography laboratories could cite structural studies that 
have been delayed for years by problems with protein crystal growth. For example, 
the relative importance of the difficulties encountered with growing crystals that are 
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suitable for complete structural studies can be seen from our experiences in  
Birmingham with the enzyme human purine nucleoside phosphorylase (PNP), which 
is a trimeric protein with a molecular weight of about 97,000. We began our efforts 
to crystallize PNP in 1975, using enzyme isolated from several different sources. 
These efforts continued until 1981, when the first usable crystals of human PNP 
were grown (48). At the present time (early 19871, we have complete data sets 
collected for about one dozen substrate, substrate analog, and inhibitor complexes of 
PNP; we have refined the structure at 3.2 A resolution (49); and we are well along 
with the 2.7 A refinement of the structure. We had the benefit of most modern 
developments in protein crystallography, including map modification techniques, 
synchrotron data, molecular graphics for constructing and interpreting models, and 
automated refinement by restrained least-squares. The main point behind this 
history is that it took about twice as long to get usable crystals as it did to do the rest 
of the crystallography. Once we had suitable crystals, the project advanced fairly 
rapidly. Clearly, crystal growth was the major obstacle in the development of this 
research project. Even the best crystals that we now have are not highly ordered, 
which causes problems in efforts to refine the structure of the protein. 
3. Microgravity applications to protein crystal growth studies 
One interesting new development in protein crystal growth involves studies of 
crystal growth under the microgravity conditions that are available in  space. 
Crystal growth has been of considerable interest to NASA and to other space- 
oriented researchers for a number of years (661, and various fundamental studies of 
crystal growth in space are in progress. The major motivation behind undertaking 
these space experiments is to examine the effects that density-driven convective flow 
has on crystal growth. In the absence of gravity, these density-driven convective 
flow effects are eliminated, thus permitting the role of convection on crystal growth 
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to be examined directly. In addition to the possibility of suppressing convective flow 
effects, microgravity conditions may also serve to minimize sedimentation, which 
can interfere with uniform growth of protein crystals. Another potential advantage 
of microgravity is the option of doing containerless crystal growth. Contacts with 
vessel walls can lead to heterogeneous nucleation. In the absence of gravity, it is 
possible to form stable spherical droplets of crystallizing materials, which may be 
suspended by acoustical levitation, air streams or other methods. It is also possible 
to form relatively large, stable droplets of aqueous solutions by simply extruding the 
solutions from a pipette or a syringe; thus protein crystals might be grown in 
relatively large droplets adhering to syringe tips, without the extensive wall effects 
that generally accompany crystallization experiments on earth. 
Several projects to study protein crystal growth in space are now in progress 
(50-54). In addition, investigators at  the Marshall Space Flight Center and other 
researchers supported by NASA, who have considerable background experience in 
fluid mechanics and crystal growth theory, are now turning their attention and 
diverse disciplines to fundamental investigations of protein crystal growth. 
Although it  is not clear at  this stage if microgravity conditions will prove of general 
importance in significantly enhancing the growth of protein crystals, the space 
experiments should make it possible to control parameters that would be difficult or 
impossible to control on earth. Thus these space experiments should prove useful in 
better understanding the principles, and the limiting factors in protein crystal 
growth. 
NASA-sponsored space shuttle experiments in protein crystal growth 
The space shuttle experiments have been described in considerable detail in 
the literature (53,54). 
One of the most widely used methods of crystallizing proteins on earth involves 
the slow precipitation of protein from droplets of solution by vapor pressure 
equilibration against a solution containing a higher concentration of the 
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precipitating agent. The “hanging-drop method” is a common version of this general 
technique. Most protein crystallography laboratories have extensive experience 
with vapor-diffusion crystallization methods, and a large percentage of the protein 
crystals described in recent publications have been obtained by these methods. 
In order to evaluate the possible effects of microgravity on protein crystal 
growth, it will be necessary to investigate a range of different types of proteins that 
have been well-characterized in ground-based studies. Many of the proteins that are 
being extensively studied in crystallography laboratories around the world are only 
available in milligram quantities. Vapor diffusion techniques are particularly 
suitable for crystallization experiments involving small quantities of protein and 
can be used for most types of biological materials. Therefore, we focused our initial 
experiments on development of a microgravity-adapted version of the popular 
hanging-drop method. 
Prototype flight hardware for growing protein crystals by vapor-diffusion 
methods was developed, tested, and improved through a series of four shuttle flights 
in 1985 and 1986 (STS-51D, STS-51F, STS-61B and STS-61C). These experiments 
were performed in the middeck area of the shuttle. Although the prototype 
hardware was expected to be useful for testing concepts and developing the basic 
techniques for protein crystal growth in space, it was clear that it would be of limited 
value for performing systematic experiments in protein crystal growth, since 
relatively few samples could be included and important variables such as 
temperature could not be controlled. 
The shuttle experiments were especially useful for optimizing the major 
variables in vapor diffusion protein crystal growth. We performed various 
experiments related to drop stability and found that large droplets (30-80 pl) are 
stable on blunt syringe tips even when maneuvering rockets were fired while in 
orbit. Polypropylene syringes with flared tips, and blunt end glass syringe tips in 
several different diameters, with and without various types of coatings, have now 
been used successfully for retaining droplets of protein solutions. Although protein 
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crystals have been grown in droplets as large as 80 pl, the experiments to date 
indicate that smaller droplets will assure complete equilibration during the limited 
period (3-6 days) available for protein crystal growth on space shuttle missions. In 
the most recent set of shuttle experiments (on STS-61C), 30 and 40 p1 droplets were 
used with good results. Ground-based and flight experiments also have provided 
qualitative information about equilibration rates within the vapor diffusion 
chambers. These studies have suggested that equilibration rates are significantly 
slower under micogravi ty conditions, presumably because of suppressed convection 
effects. The vapor equilibration chambers have now been designed to accelerate 
these equilibration rates. In addition, a reliable technique for seeding droplets of 
protein solutions within the vapor diffusion apparatus has been developed, and has 
been used to grow crystals of human C-reactive protein. 
During the most recent shuttle experiments on STS-61C, crystals were grown 
of all proteins that were tested, including hen egg white lysozyme, human serum 
albumin, human C-reactive protein, bacterial purine nucleoside phosphorylase, 
canavalin, and concanvalin B. That particular shuttle mission was prematurely 
shortened, and the protein crystal growth experiments were deactivated during the 
third day of the flight. Although many of the protein solutions had not completely 
equilibrated during that period of time, relatively large X-ray quality crystals were 
obtained for all of the proteins except lysozyme. 
Comprehensive studies of the effects of microgravity on protein crystal growth 
will be made on future shuttle flights, using equipment based on the prototype 
system that was flown on STS-61C. Although quantitative conclusions about 
protein crystal growth cannot be made a t  this stage, there are several interesting 
qualitative observations that have been made during these preliminary shuttle 
experiments. 
It appears that the elimination of density-driven sedimentation can affect 
crystal morphology, The best example of this is canavalin, which grew crystals that 
were dispersed through the droplets in space. Nearly all the space-grown canavalin 
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crystals appear to have formed from separate nucleation sites, resulting in uniform 
morphologies. On the other hand, canavalin crystals grown by this method on earth 
generally form as fused aggregates at the bottom of the droplets. In the case of 
human C-reactive protein, an entirely new crystal form, which had not previously 
been identified in ground-based crystal growth experiments, was obtained from 
shuttle experiments. Crystallization of C-reactive protein has  been studied 
extensively over the past eight years in Birmingham and only one crystal form, with 
space group P4122 (or P4322) has been obtained in these experiments. A new crystal 
form was first observed for C-reactive protein from experiments on STS-GlB, and 
copious quantities of this crystal form were obtained on STS-61C. The space group 
for the new crystal form is P4222, and i t  diffracts to an appreciably higher resolution 
than the original crystal form. The new crystal form has now been obtained in 
ground-based experiments using the shuttle hardware, so it may be influenced by 
altered equilibration rates or other experimental conditions that  are hardware 
dependent. It is not yet clear how microgravity affects the distribution of these two 
crystal forms of human C-reactive protein. 
It is not yet clear if the internal order or diffraction resolutions of space-grown 
protein crystals are significantly different from that of crystals grown on earth. It 
will be necessary to do detailed comparisons involving large numbers of crystals 
grown under well-controlled conditions on earth and in space, before the potential 
effects of microgravity on protein crystal quality can be evaluated. 
Summary 
Protein crystal growth is a major experimental problem and is the bottleneck 
in widespread applications of protein crystallography. Research efforts now being 
pursued and sponsored by NASA are making fundamental contributions to our 
understanding of the science of protein crystal growth. Microgravity environments 
offer the possibility of performing new types of experiments that may produce a 
better understanding of protein crystal growth processes and may permit growth 
environments that are more favorable for obtaining high-quality protein crystals. 
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A series of protein crystal growth experiments using the space shuttle has been 
initiated. The first phase of these experiments has been focused on the development 
of micro-methods for protein crystal growth by vapor diffusion techniques, using a 
space version of the hanging-drop method. The preliminary space experiments have 
been used to evolve prototype hardware that will form the basis for a more advanced 
system that can be used to evaluate effects of gravity on protein crystal growth. 
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